Cardiovascular Systems to Webcast Fiscal 2013 Third-Quarter Earnings
Conference Call Wednesday, May 1
Live Webcast at 3:45 p.m. CT (4:45 p.m. ET)
ST. PAUL, Minn. -- April 24, 2013
Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII) will host a live webcast of
its fiscal 2013 third-quarter conference call on Wednesday, May 1, 2013, at
3:45 p.m. CT (4:45 p.m. ET). David Martin, president and chief executive
officer, and Larry Betterley, chief financial officer, will discuss the
company’s results for its fiscal third quarter ended March 31, 2013, and its
financial outlook. The company will issue a post-market earnings release prior
to the call on May 1.
To access the live webcast, go to the investor section of the company’s
website, www.csi360.com, on the day of the conference call and click on the
webcast icon. A webcast replay will be available beginning at 5:45 p.m. CT the
To participate in the conference call, dial (888) 713-4205 and enter 48810662.
Please dial in at least 10 minutes prior to the call. To pre-register for the
call, log on to the following website:
joining the call, pre-registered participants can enter their PIN code, and
other participants can press *0 to reach the operator, or wait on the line for
If you do not have access to the Internet and want to listen to an audio
replay of the conference call, dial (888) 286-8010 and enter access number
46269911. The audio replay will be available beginning at 5:45 p.m. CT on
Wednesday, May 1, 2013, through 11 p.m. CT on Wednesday, May 8, 2013.
About Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device
company focused on developing and commercializing innovative solutions for
treating vascular and coronary disease. The company’s Orbital Atherectomy
Systems treat calcified and fibrotic plaque in arterial vessels throughout the
leg in a few minutes of treatment time, and address many of the limitations
associated with existing surgical, catheter and pharmacological treatment
alternatives. The U.S. Food and Drug Administration (“FDA”) granted 510(k)
clearance for the use of the Diamondback Orbital Atherectomy System in August
2007. To date, over 100,000 of CSI’s devices have been sold to institutions
across the United States. CSI recently completed its ORBIT II Investigational
Device Exemption clinical trial to evaluate the safety and effectiveness of
its orbital technology in treating coronary arteries and submitted its
Premarket Approval (“PMA”) application to the FDA on March 15, 2013. The
coronary system is limited by federal law to investigational use and is
currently not commercially available in the United States.
For more information, visit the company’s website at www.csi360.com.
Cardiovascular Systems, Inc.
Investor Relations, 651-259-2800
Padilla Speer Beardsley Inc.
Marian Briggs, 612-455-1742
Matt Sullivan, 612-455-1709
Press spacebar to pause and continue. Press esc to stop.